SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365: 6062.
  • 2
    The ATAC Trialists' Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006; 7: 633643.
  • 3
    Cuzick J,Wale C; on Behalf of the ATAC Trialists' Group. A detailed analysis of the benefits of anastrozole over tamoxifen for venous thromboembolic events (VTEs) after 5 years treatment. Presented at the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 14-17, 2006. Abstract 104.
  • 4
    Eastell R,Hannon RA,Cuzick J, et al. Effect of anastrozole on bone mineral density: 5-year results of the ‘Arimidex’ (anastrozole), Tamoxifen, Alone or in Combination (ATAC) trial [abstract OC002]. Calcif Tissue Int. 2006; 78( suppl 1): S25.
  • 5
    Duffy S; on behalf of the ATAC Trialists' Group. Anastrozole is associated with a lower risk of endometrial abnormalities than tamoxifen: first report of the ATAC trial endometrial subprotocol at 6 years' follow-up [poster 4055]. Presented at the San Antonio Breast Cancer Symposium, San Antonio, Tex, December 14-17, 2006.
  • 6
    Cella D,Fallowfield L,Barker P,Cuzick J,Locker G,Howell A. Quality of life of postmenopausal women in the ATAC (“Arimidex,” Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treatment. 2006; 100: 273284.
  • 7
    Breast International Group 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005; 353: 27472757.
  • 8
    Coates AS,Keshaviah A,Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007; 25: 486492.
  • 9
    Kaufmann M,Jonat W,Hilfrich J, et al. Survival benefit of switching to anastrozole after 2 years' treatment with tamoxifen versus continued tamoxifen therapy: the ARNO 95 study. ASCO Meeting Abstracts. 2006; 24(18s). Abstract 547.
  • 10
    Jakesz R,Jonat W,Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005; 366: 455462.
  • 11
    Boccardo F,Rubagotti A,Guglielmini P, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian Tamoxifen Anastrozole (ITA) trial. Ann Oncol. 2006; 17( suppl 7): vii10vii14.
  • 12
    Jonat W,Gnant M,Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 2006; 7: 991996.
  • 13
    Coombes RC,Hall E,Gibson LJ, et al. A Randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004; 350: 10811092.
  • 14
    Coombes RC,Kilburn LS,Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet. 2007: 369; 559570.
  • 15
    Coleman RE,Banks LM,Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007; 8: 11191127.
  • 16
    Fallowfield LJ,Bliss JM,Porter LS, et al. Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol. 2006; 24: 910917.
  • 17
    Goss PE,Ingle JN,Silvana Martino DO, et al. A randomized trial of letrozole in postmenopausal women after 5 years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003; 349: 17931802.
  • 18
    Pfizer Inc. New study shows efficacy of aromasin on early breast cancer. Breast Cancer News. December 18, 2006.
  • 19
    Jakesz R,Samonigg H,Greil R, et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). ASCO Meeting Abstracts. 2005; 23(10s). Abstract 527.